Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control

References

• PrabhakarUMaedaHJainRKChallenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyCancer Res2013732412241723423979
   PubMed Web of Science ®Google Scholar
• DanhierFFeronOPreatVTo exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug deliveryJ Control Release201014813514620797419
   PubMed Web of Science ®Google Scholar
• KobayashiHWatanabeRChoykePLImproving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?Theranostics20134818924396516
   PubMed Web of Science ®Google Scholar
• VendittoVJSzokaFCJrCancer nanomedicines: so many papers and so few drugs!Adv Drug Deliv Rev201365808823036224
   PubMed Web of Science ®Google Scholar
• O’BrienMEWiglerNInbarMReduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerAnn Oncol20041544044914998846
   PubMed Web of Science ®Google Scholar
• HarrisLBatistGBeltRLiposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinomaCancer200294253611815957
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol2005237794780316172456
   PubMed Web of Science ®Google Scholar
• SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol2012302055206222547591
   PubMed Web of Science ®Google Scholar
• DriscollJJRixeOOverall survival: still the gold standard. Why overall survival remains the definitive end point in cancer clinical trialsCancer J20091540140519826360
   PubMed Web of Science ®Google Scholar
• MarkmanMIntraperitoneal antineoplastic drug delivery: rationale and resultsLancet Oncol2003427728312732164
   PubMed Web of Science ®Google Scholar
• CeelenWPFlessnerMFIntraperitoneal therapy for peritoneal tumors: biophysics and clinical evidenceNat Rev Clin Oncol2010710811520010898
   PubMed Web of Science ®Google Scholar
• MinchintonAITannockIFDrug penetration in solid tumoursNat Rev Cancer2006658359216862189
   PubMed Web of Science ®Google Scholar
• BharaliDJMousaSAEmerging nanomedicines for early cancer detection and improved treatment: current perspective and future promisePharmacol Ther201012832433520705093
   PubMed Web of Science ®Google Scholar
• LapennaSGiordanoACell cycle kinases as therapeutic targets for cancerNat Rev Drug Discov2009854756619568282
   PubMed Web of Science ®Google Scholar
• ChouTCDrug combination studies and their synergy quantification using the Chou-Talalay methodCancer Res20107044044620068163
   PubMed Web of Science ®Google Scholar
• NagayasuAUchiyamaKKiwadaHThe size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugsAdv Drug Deliv Rev199940758710837781
   PubMed Web of Science ®Google Scholar
• HiguchiTRate of release of medicaments from ointment bases containing drugs in suspensionJ Pharm Sci19615087487513907269
   PubMed Web of Science ®Google Scholar
• NounouMMEl-KhordaguiLKKhalafallahNAKhalilSAIn vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gelsActa Pharm20065631132419831280
   PubMedGoogle Scholar
• LindholmAKahanBDInfluence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantationClin Pharmacol Ther1993542052188354028
   PubMed Web of Science ®Google Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev20065862168116968952
   PubMed Web of Science ®Google Scholar
• AlbertsDSLiuPYHanniganEVIntraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancerN Engl J Med1996335195019558960474
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med2006354344316394300
   PubMed Web of Science ®Google Scholar
• MuntzHGMalpassTWMcGonigleKFRobertsonMDWeidenPLPhase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinomaCancer200811349049618521923
   PubMed Web of Science ®Google Scholar
• DelgadoGPotkulRKTreatJAA phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancerAm J Obstet Gynecol19891608128172712114
   PubMed Web of Science ®Google Scholar
• TriolaMFElementary Statistics12th edUpper Saddle River, NJ, USAPearson Education Limited2014
   Google Scholar
• LengyelEOvarian cancer development and metastasisAm J Pathol20101771053106420651229
   PubMed Web of Science ®Google Scholar
• AllisonKHFlignerCLParksWTRadiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy casesArch Pathol Lab Med20041281418142315578887
   PubMed Web of Science ®Google Scholar
• BabaTUramotoHKuwataTIntrapleural chemotherapy improves the survival of non-small cell lung cancer patients with positive pleural lavage cytologySurg Today20134364865322855011
   PubMed Web of Science ®Google Scholar
• LombardiGNicolettoMOGusellaMIntrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysisCancer Chemother Pharmacol20126978178722037881
   PubMed Web of Science ®Google Scholar
• LiuJMeisnerDKwongEWuXYJohnstonMRTranslymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable paclitaxel colloids controls lymphatic metastasis in lung cancerCancer Res2009691174118119176391
   PubMed Web of Science ®Google Scholar
• GervasoniJEJrTanejaCChungMACadyBBiologic and clinical significance of lymphadenectomySurg Clin North Am2000801631167311140865
   PubMed Web of Science ®Google Scholar
• HalkiaESpiliotisJSugarbakerPDiagnosis and management of peritoneal metastases from ovarian cancerGastroenterol Res Pract2012201254184222888339
   PubMed Web of Science ®Google Scholar
• KondoTStem cell-like cancer cells in cancer cell linesCancer Biomark2007324525017917153
   PubMedGoogle Scholar
• HarlessWWCancer treatments transform residual cancer cell phenotypeCancer Cell Int201111121214935
   PubMed Web of Science ®Google Scholar
• HelmCWCurrent status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancerSurg Oncol Clin N Am20122164566323021722
   PubMed Web of Science ®Google Scholar
• ParkerRJHartmanKDSieberSMLymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to ratsCancer Res198141131113177214320
   PubMed Web of Science ®Google Scholar
• PatelKRBaldeschwielerJDMouse Lewis lung carcinoma and hepatoma ascites treatment by combination of liposome chemotherapy and non-specific immunotherapyInt J Cancer1984347177236389375
   PubMed Web of Science ®Google Scholar
• LeungAWKalraJSantosNDBallyMBAnglesioMSHarnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatmentsNanomedicine (Lond)2014950152224746193
   PubMed Web of Science ®Google Scholar
• NguyenLVVannerRDirksPEavesCJCancer stem cells: an evolving conceptNat Rev Cancer20121213314322237392
   PubMed Web of Science ®Google Scholar
• PolyakKWeinbergRATransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traitsNat Rev Cancer2009926527319262571
   PubMed Web of Science ®Google Scholar
• CojocMPeitzschCTrautmannFEmerging targets in cancer management: role of the CXCL12/CXCR4 axisOnco Targets Ther201361347136124124379
   PubMedGoogle Scholar
• SinghASettlemanJEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerOncogene2010294741475120531305
   PubMed Web of Science ®Google Scholar
• ZhaoYAlakhovaDYKabanovAVCan nanomedicines kill cancer stem cells?Adv Drug Deliv Rev2013651763178324120657
   PubMed Web of Science ®Google Scholar
• EliasDQuenetFGoereDCurrent status and future directions in the treatment of peritoneal dissemination from colorectal carcinomaSurg Oncol Clin N Am20122161162323021719
   PubMed Web of Science ®Google Scholar
• JacquetPAverbachAStuartOAChangDSugarbakerPHHyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat modelCancer Chemother Pharmacol1998411471549443628
   PubMed Web of Science ®Google Scholar
• YanTDBlackDSugarbakerPHA systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancerAnn Surg Oncol2007142702271317653801
   PubMed Web of Science ®Google Scholar
• YanTDBlackDSavadyRSugarbakerPHA systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritoneiAnn Surg Oncol20071448449217054002
   PubMed Web of Science ®Google Scholar
• Di MiceliDAlfieriSCaprinoPComplications related to hyperthermia during hypertermic intraoperative intraperitoneal chemotherapy (HIPEC) treatment. Do they exist?Eur Rev Med Pharmacol Sci20121673774222913203
   PubMed Web of Science ®Google Scholar
• GlantzMJLaFolletteSJaeckleKARandomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitisJ Clin Oncol1999173110311610506606
   PubMed Web of Science ®Google Scholar
• PasquierEKieranMWSterbaJMoving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric OncologyTransl Oncol2011420321121804915
   PubMed Web of Science ®Google Scholar
• PasquierEKavallarisMAndreNMetronomic chemotherapy: new rationale for new directionsNat Rev Clin Oncol2010745546520531380
   PubMed Web of Science ®Google Scholar